Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CET

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
07:03a Merck raises stakes in lung cancer as rivals close in
05:37a ASTRAZENECA : Watch Out For BLUE, BPMC, GBT, KURA, KDMN, SYRS Today
12/10 ASTRAZENECA : ’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lym..
12/09 ASTRAZENECA : ’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relap..
12/08 ASTRAZENECA : to highlight its commitment to blood cancers at the 2017 American ..
12/07 ASTRAZENECA : Researchers at AstraZeneca Report Findings in Chemical Biology (Id..
12/07 ASTRAZENECA : Reports on Non-Small Cell Lung Cancer Findings from AstraZeneca Pr..
12/07 ASTRAZENECA : Reports from AstraZeneca Describe Recent Advances in Capsaicin (XE..
12/07 ASTRAZENECA : Drugmakers line up to invest in UK life sciences
12/07 U.K. unveils life sciences sector deal
More news
News from SeekingAlpha
12/09 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 9, 2017
12/07 Pieris on go with early-stage study of inhaled therapy for treatment-resistan..
12/07 TESARO : Updates To Thesis
12/06 CLOVIS ONCOLOGY : 2018 Turnaround Story
12/06 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Galectin's Failure, Revance's Positive Re..
Financials ($)
Sales 2017 21 817 M
EBIT 2017 5 884 M
Net income 2017 2 293 M
Debt 2017 12 395 M
Yield 2017 4,26%
P/E ratio 2017 32,28
P/E ratio 2018 27,25
EV / Sales 2017 4,28x
EV / Sales 2018 4,28x
Capitalization 81 090 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 68,3 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA6.41%81 598
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559